The combined strategy of the MEK inhibitor trametinib plus the RTK inhibitor anlotinib effectively inhibits the feedback activation of ERK and results in long-term inhibition of AKT in KRAS-mutant NSCLC, preliminarily explaining the synergistic antitumor activity. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.